Steven J. Evans, M.D.
Chief Executive Officer, Director

Dr. Evans is a leading strategic advisor in life sciences with 20+ years of experience working in the medical device sector. He is co-inventor, co-founder, former CEO and Director at ImaCor Medical Technologies. He obtained his medical degree from New York University School of Medicine, completed his fellowship in Cardiovascular Disease and Electrophysiology at Cedars-Sinai Hospital, and served as Chief of EP at Long Island Jewish Hospital and Beth Israel Medical Center.

Itzhak Kelson, Ph.D.
Founder, Chairman and Chief Technology Officer

Prof. Itzhak Kelson is a retired Chairman of the Tel Aviv University Physics Department. He has held research and teaching positions at the Weizmann Institute, Yale University, Lawrence Livermore National Laboratory, University of Wisconsin, Brookhaven National Laboratory, and other institutions.

Yona Keisari, Ph.D.
Founder and Chief Scientific Officer

Prof. Yona Keisari is a member of the Human Microbiology Dept., Tel Aviv University. He has held fellowships and research appointments at many international centers of cancer research including the NIH and MD Anderson.

Etan Hillman
Chief Financial Officer

Mr. Hillman has many years experience in international business and management both in Israel and the USA. He is a former President of the Israel Venture Association (IVA). He has a B.A. degree from the Hebrew University in Jerusalem in Economics and an MBA from NYU.

Patrick Lopath, M.B.A
Chief Operating Officer

Mr. Lopath is a medical device engineer and inventor or co-inventor on 12 US patents. He joined Althera after a number of years in management consulting working with leading life science firms on operational strategy. He received his undergraduate degree in Biomedical Engineering and MBA at Duke University and a Masterís degree in Bioengineering from the Pennsylvania State University.

C. Leonard Gordon, Esq.
Chairman and Director

An attorney with experience in law and business, including 25 years in every aspect of medical venture capital.